BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

BCLI$1.14-7.3%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM · Page
· PART I ·
1.	Business	4
1A.	Risk Factors	37
1B.	Unresolved Staff Comments	69
2.	Properties	70
3.	Legal Proceedings	70
4.	Mine Safety Disclosures	71
· PART II ·
5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	72
6.	Reserved	72
7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	72
7A.	Quantitative and Qualitative Disclosures About Market Risk	77
8.	Financial Statements and Supplementary Data	78
9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	109
9A.	Controls and Procedures	109
9B.	Other Information	110
9C.	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	110
· PART III ·
10.	Directors, Executive Officers and Corporate Governance	111
11.	Executive Compensation	119
12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	125
13.	Certain Relationships and Related Transactions, and Director Independence	127
14.	Principal Accounting Fees and Services	130
· PART IV ·
15.	Exhibits, Financial Statement Schedules	131

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents